Dr. Ariel Orbach has been a part of Marx Biotechnology since its founding, as the Chief Technical Officer (CTO). Prior to joining Marx Bio, he played a key role in R&D at Silenseed, a biotechnology company which is developing cancer therapies based on siRNA and combined with an innovative drug delivery method. Dr. Orbach has deep experience in running clinical trials and has led projects from the level of basic research all the way to the FDA approval process. Dr. Orbach originally received a Ph.D. in immunology from the Hebrew University. He conducted research on the role of fusion proteins in immuno-suppression, which went on to testing for clinical use
Immunology